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In 2010, the Washington Circle convened a meeting, supported by the National Institute on Drug Abuse (NIDA) and
the Substance Abuse and Mental Health Services Administration (SAMHSA), for a multidisciplinary group of experts
to focus on the research gaps in performance measures for substance use disorders. This article presents
recommendations in three areas: development of new performance measures; methodological and other
considerations in using performance measures; and implementation research focused on using performance
measures for accountability and quality improvement.
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Two decades ago, the Institute of Medicine defined qual-
ity as “the degree to which health care services for indi-
viduals and populations increase the likelihood of
desired health outcomes and are consistent with current
professional knowledge” [1]. Today, performance mea-
sures, the metrics used to measure the quality of health-
care, play increasingly important roles in all aspects of
healthcare.
In particular, the increased focus on performance mea-
sures that address the prevention and treatment of sub-
stance use disorders has been driven by new legislative
initiatives. The 2010 Patient Protection and Affordable
Care Act has the potential to open up treatment for sub-
stance use disorders to more Americans. The 2008 Men-
tal Health Parity and Addiction Equity Act expands
benefits for mental and substance use disorders. The
Health Information Technology for Economic and Clin-
ical Health Act (HITECH Act) encourages the promul-
gation of electronic health records and incentives for
performance measurement. In addition, widespread pay-
ment reforms, including incentive–based approaches,
are leading to an ever stronger focus on the accountabil-
ity of clinicians and treatment programs for providing
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reproduction in any medium, provided the orGiven the high stakes uses of performance measures,
it is crucially important that performance measures fo-
cused on substance use disorders be further developed,
be critically examined, and be implemented in the con-
text of a changing health care system [2]. Therefore, in
March 2010, the Washington Circle convened a meeting
of payers, consumers, providers, policy makers and
researchers to discuss the state of performance measures
and to develop a research agenda to address current def-
icits. The Washington Circle is a group of national
experts on substance abuse policy, research, and per-
formance measurement that seeks to improve the quality
and effectiveness of prevention and treatment services
through the use of performance measures [3]. This
meeting was supported by the Substance Abuse and
Mental Health Services Administration (SAMHSA) and
the National Institute on Drug Abuse (NIDA).
Specifically, the participants’ charge was to: review the
current status of performance measures focused on sub-
stance use disorders; identify gaps in currently available
measures and opportunities for research, in light of our
current understanding of addictive disease and recovery;
and develop a research agenda. Rather than set out a
concise list of research priorities, the participants fo-
cused on developing a range of suggestions. In reporting
on this meeting, our goal is to stimulate new research
on performance measurement by drawing connections
to and making suggestions about areas that need focused
attention.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for developing a research agenda for performance mea-
sures for substance use disorders and present the recom-
mendations. This report builds on a foundation of
earlier work, including the Institute of Medicine Report:
Improving the Quality of Health Care for Mental and
Substance-Use Conditions [4], a background paper com-
missioned for that report [5], and a recent article on pri-
orities for policy research [6].
Context
Timothy Condon (National Institute on Drug Abuse)
emphasized that performance measurement needs to be
considered in the context of developments in our under-
standing of substance use disorders, of newly emerging
standards of care, and of behavioral health more broadly,
as well as in the context of general medical care. In-
creasingly, common thinking has shifted from consider-
ing substance misuse to be a human failing to an
understanding that addiction is a treatable disease. Clin-
ical research has revealed the role of genetics in vulner-
ability to addiction, changes in brain functioning that
make voluntary behavior different after addiction than in
the absence of addiction, and the role of social/cultural
environment in addiction. Thus, the most effective treat-
ment strategies will attend to all aspects of addiction, in-
cluding biology, behavior and social context. It is key to
consider these aspects of the nature of addiction in
developing a research agenda on performance measure-
ment [5]. There is an emerging consensus that addiction
is often a chronic condition akin to other chronic condi-
tions in the medical sphere with similar rates of non-
adherence to treatment and relapse.
Mady Chalk (Treatment Research Institute) pointed
out that there is a well-studied repertoire of interven-
tions to treat addiction or to change unhealthy patterns
of use which has provided additional impetus to
the development of measures. Although there are
evidence-based approaches to addiction treatment, their
implementation remains challenging because of limita-
tions involving organizational readiness, resources, and
leadership [7].
Describing the landscape of performance measure-
ment, Constance Horgan (Brandeis University) empha-
sized that a decade ago, only a handful of organizations
focused on performance measurement, while today a
plethora of groups are developing, testing, endorsing,
using, or selling measures in the general medical sector.
Several leading organizations include a specific focus on
performance measures for substance use disorders in
their current initiatives including the National Quality
Forum (NQF), the National Committee on Quality Assur-
ance (NCQA), and the American Medical Association
(AMA). Many other groups are incorporating performancemeasures for substance use disorders into their broad-
based measure development initiatives. One promising
measurement approach is to consider individuals’ multiple
interactions with the health care system through compos-
ite measures which allow for a more integrated assessment
of performance that can include behavioral as well as gen-
eral medical conditions.
Research recommendations
The meeting participants were asked to focus their
recommendations in three areas: development of new
performance measures; methodological and other con-
siderations in using performance measures; and imple-
mentation research focused on using performance
measures for accountability and quality improvement.
During the meeting, the participants did not prioritize
among their many research recommendations, although
there was general consensus that work is needed in all
three broad areas. In this section, we review these
recommendations and outline their rationales.
Development of new performance measures
Developing new performance measures is challenging
because they need to meet several criteria, including im-
portance, scientific soundness and feasibility [5,8]. En-
dorsement by the National Quality Forum (NQF) is
required for measures to be used in Federal programs,
and the endorsement process imposes a high level of
rigor with respect to these standards of specification
and testing. The meeting participants recommended
development across a balance of types of measures -
structural, process, and outcome measures. The group
also recommended consideration of composite measures
that aggregate multiple domains and stressed the need
to establish associations between structural or process
measures and outcomes.
Development of structural measures
Structural measures are features of a healthcare
organization or health system that are focused on its
capacity to provide health care. They are often used in
contracts between health plans and managed behavioral
healthcare organizations, and in accreditation of facil-
ities. For example, in the NCQA accreditation of mana-
ged behavioral healthcare organizations, structural
measures are included to determine whether there are
practitioners located throughout the service area and
whether there are sufficient numbers of practitioners
[9,10]. Promising areas for development of new struc-
tural measures should build on current research on best
management practices in the following areas:
 Inclusion of medications to treat addictive disorders
on a health plan’s formulary. For example, this
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alcohol abuse and dependence, and buprenorphine
and methadone for opioid dependence.
 Rate of collecting and reporting data on clients’
perceptions of care using standardized instruments
(e.g., the ECHO or Modular survey). Surveying
clients is consistent with the national priority for
patient-centered care.
 Measures of management practices. This may
include whether treatment organizations have
business practices in place that are associated with
better treatment processes, such as management
practices that have been found to be associated with
shorter wait times from first contact to treatment
admission [11].
 Measures of connections between organizational
providers across the continuum of treatment services.
This includes a range of efforts that support care
coordination including communication, networks, or
contract elements between providers of residential
and of follow-up outpatient services.
Development of process measures
These measures are used to assess a health care service
provided to, or on behalf of patients. Often they are used
to assess adherence to recommendations for clinical
practice based on evidence or consensus. For example,
measures of initiation and engagement developed by the
Washington Circle [12-14] are already being used exten-
sively by, among others, the National Committee for
Quality Assurance [15], the Department of Veterans
Affairs (VA) [16,17] and several states [14]. Related mea-
sures for access to and retention in treatment have been
developed by the Network for the Improvement of Ad-
diction Treatment (NIATx) [18-21]. Clinical perform-
ance measures for physicians were developed by the
Physician Consortium for Performance Improvement
(PCPI), convened by the American Medical Association;
these include counseling regarding psychosocial and
pharmacologic treatment options for alcohol and opioid
dependence, and screening and brief counseling for
unhealthy alcohol use [22]. Recently, the Washington
Circle released specifications for two new measures on
MAT, focused on overall use of appropriate medications
for substance abuse disorders and on the timely initi-
ation of medications in newly treated individuals [23,24],
although development of additional measures focused
on adherence rates and clinical follow-up after initiation
of medications is still needed.
While recognizing the advances made in developing
process measures, the meeting participants also noted
some gaps and the need to develop additional measures,
consistent with findings from clinical or services
research: Measures to monitor screening and brief intervention
services for unhealthy alcohol use. These measures
might take advantage of recently adopted procedure
codes [25].
 Maintenance of treatment effects. These include
recovery support and retention, going beyond
counting units and timing of services to also focus
on treatment intensity and quality of engagement
and the therapeutic relationship.
 Measures tailored for specific groups of clients. Based
on results of research showing which treatment
approaches are most effective for specific groups,
measures might be tailored specifically for women,
individuals released from incarceration or
adolescents.
As Alexander Harris reported (Palo Alto Veterans
Administration (VA) Healthcare System), the literature
assessing the relationship between process or structural
performance measures and outcomes has not received
sufficient attention. In the past few years, research has
begun to be published on the association of some
process measures and outcomes, although the findings
are mixed. Clients with a new outpatient treatment epi-
sode who engaged in treatment were less likely to be
arrested or incarcerated the following year [26,27].
Adolescents in residential treatment achieving continu-
ity of care after treatment were significantly more
likely to be abstinent at 3-months post-discharge [28].
VA patients who met engagement criteria had signifi-
cantly greater reductions in addiction severity than
those who did not. However, although statistically sig-
nificant, those reductions were found to be clinically
modest [16].
Further studies are crucial to better understand the
nuances of associations between improvements in
structural or process performance measures and
improvements in clients’ outcomes as well as lower
costs or better efficiency in the treatment system.
These studies should be focused both on existing per-
formance measures and on new measures as they are
developed. Indeed, testing the association of alternate
specifications of structural or process measures can be
built into routine measure development [29]. More-
over, it is critical to assess if any association varies by
client group (e.g., gender, race/ethnicity, or age) or
treatment setting.
Development of outcome measures
These measures, focusing on health states resulting from
health care practices and interventions, generally reflect
the cumulative impact of multiple processes of care [30].
For substance use disorders, commonly used outcome
measures go beyond the measures of clinical outcomes
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include non-clinical outcomes such as: stable and sup-
portive housing [31-34]; employment (for adults), educa-
tional involvement (for adolescents); and decreased
criminal justice involvement. In addition, it is recognized
that a broad group of service systems extending beyond
the medical sector provide a coordinated menu of ser-
vices and supports to maximize outcomes, e.g. recovery
support, family, housing/homeless, child welfare, educa-
tion, and criminal justice [35].
Given this context, additional development of per-
formance measures focused on outcomes is needed in
the following area:
 Measures that consider addiction as a chronic
condition [36] and explore the emerging construct of
recovery as it becomes more deconstructed and
operationalized [37]. Initial efforts are needed to
prioritize which new measures are needed, such as
well-being, severity of alcohol or substance use, days
of use, functionality in work and home life, and
health status. The next step is translating these
concepts into measure specifications.
Development of composite measures
These measures go beyond single structural, process, or
outcome measures. They combine multiple measures to
give a broader picture of performance, but they may be
complex to interpret and next steps in quality improve-
ment may not be clear. For example, while there is some
work on performance measures for co-occurring sub-
stance use disorders and mental health problems [38],
little research has been focused on performance mea-
sures for treatment of clients who have co-occurring
substance use disorders and chronic medical conditions.
Participants also recommended that new composite
measure development should also be considered in the
following areas:
 Composite process measures that aggregate current
substance abuse treatment process measures for a
specific client. For example, a composite could
include whether the client become engaged in
treatment and was offered medication
assisted treatment.
 Composite process measures that incorporate
multiple components of the process of care for
substance use disorders. This approach would
expand beyond number and timing of treatment
services to also include client perception of
the quality of visits and client behavior
indicative of engagement in the treatment
process such as web discourse with
clinicians [39]. Composite outcome measures at the client level that
aggregate multiple outcomes. This outcome-focused
composite might combine abstinence, housing and
employment.
 Composite structural measures focused on whether
an organization has a set of structural elements.
Among structural measures to consider are
organizational capacity; leadership/management;
clinical and administrative supervision functions;
documented treatment philosophies; workforce
issues/characteristics such as inclusion of case
managers, staff training/credentials, staff
productivity and performance; financial practices;
and organizational culture.
Methodological and other considerations in using
performance measures
In addition to developing performance measures, add-
itional research is needed to critically examine perform-
ance measures in three areas: design issues and their
impact on measure development and use; new sources
of information, particularly electronic health records;
and integration of performance measures with settings
outside the specialty substance abuse treatment and with
performance measures for medical conditions.
Exploration of design issues
Both new measure development and research that is fo-
cused on performance measurement should be explicit
about design issues. Otherwise the results of perform-
ance measurement can be misleading. Among the pleth-
ora of questions related to design issues, answers to the
following four are key:
 What are appropriate approaches to case mix
adjustment? This issue is crucial in adjusting for
other influences in studies of the association
between process measures and outcomes or in
considering differences among client populations in
comparisons across treatment facilities [40]. In
addition to the usual client-level variables used in
case mix adjustment (e.g., age, gender,
co-morbidities), additional variables (e.g., client
self-selection or level of substance use before entry
into treatment) also may be necessary to properly
adjust for case mix for substance use disorders.
In particular, case-mix adjustment methods should
be further developed that have the following
characteristics: availability in commonly used
datasets (currently this generally means
administrative data), illuminate any relevant
disparities in treatment (e.g., racial/ethnic, gender,
age) and can be targeted to specific populations (e.g.,
adolescents, pregnant women, individuals who are
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needs to be given to the potential for case mix
adjustment to mask important differences
across groups.
 What contributes to variation in performance
measures? This research is important for driving not
only accountability but quality improvement efforts
as well. Issues for consideration include how to
attribute performance results when treatment for
substance use disorders often is offered by a team of
clinicians or how to interpret results when clinicians
may see too few clients to make the statistics
meaningful [41]. Beyond the immediate influence of
clinician/client interactions, it also is key to
understand the extent to which variations in
performance measures results can be attributed to
system-level, facility-level, community-level, and
client-level factors and how these can be teased out.
 How is research influenced by the timing of data
collection during the course of treatment and
follow-up? By carefully considering timing of data
collection, researchers can address questions such as
what is the relationship between process measures
and outcomes related to substance use during or
shortly after treatment and more distal functional
outcomes. However, constraints may be introduced
by the availability of data. For research using
secondary data sources, data may be collected only
at admission, at 90-day follow-up periods, at time of
treatment service, or on an outcome event basis
(e.g., date of arrest).
 How does the definition of a treatment episode
influence the development of performance measures?
Decisions on when to collect outcome data or assess
process measures need to be considered in the
context of how episodes of treatment for substance
use disorders are defined (e.g., including only one
cycle of treatment or also including a period of
recovery), what constitutes termination of treatment
and how recovery is conceptualized [37,42,43].
Use of Electronic Health Records (EHRs) to incorporate new
sources of information
New information for performance measurement is on
the horizon with the accelerated pace of dissemination
of EHRs, yet most current performance measures are fo-
cused on existing administrative data sources. EHRs
have enormous potential to expand types of information,
some of which is impossible to envision today including
collection of more in-depth information, text mining of
information from clinicians’ notes using natural language
programming, blending of data across sites and systems
of care (subject to confidentiality restrictions), and on-
going data collection during the course of treatment.This information, in turn, will allow for new measure de-
velopment and implementation.
Thus, it is critical for those interested in research fo-
cused on performance measures for substance use disor-
ders to: track what areas are being targeted for inclusion
in EHRs; carefully assess what information should be
collected and what is actually being captured; ensure the
participation of providers of services for substance use
disorders in EHRs; and monitor the pace of implementa-
tion. Recently, the NIDA Clinical Trials Network (CTN)
undertook a consensus process to develop a treatment-
relevant set of common core data elements with standar-
dized vocabularies relevant to drug addiction treatment
that could be incorporated and widely adopted into har-
monized electronic medical record systems [44]. Incorp-
oration of information related to substance use disorders
into mainstream medical EHR systems, would open up
the possibility for the new development and research on
composite measures that aggregate a focus on substance
use disorders and medical conditions (e.g., diabetes,
hypertension, depression).
Despite the fast pace of EHR development and its
promise to improve the quality or performance meas-
urement, it is important to guard against inflated
expectations. In the short term, the standardized per-
formance measurement that is essential for account-
ability will still rely on more traditional information
sources, e.g., claims/encounter datasets or patient sur-
veys. At the same time, collection of expanded infor-
mation and new approaches to collecting data are also
important in order to exploit the new opportunities
that EHRs offer. As EHRs become more prevalent, the
answers to the following questions need to be
considered:
 What are treatment programs’ and clinicians’
perceptions of clinical decision-making software or
performance measures that are fed back to them
through EHRs? Qualitative studies are needed
immediately to explore treatment programs’ and
clinicians’ views about how incorporating into
EHRs performance measures or clinical
decision-making software that is designed to
improve performance can help their care of
individuals with substance use disorders. These
studies, conducted in environments both before and
after the implementation of EHRs, can help to
identify treatment program administrators’ and
clinicians’ impressions of the capacity of EHRs;
explore variations in these impressions across
geographic areas to discern if there are local
cultures around appropriate treatment; and evaluate
if clinicians’ initial impressions are confirmed when
EHRs actually are implemented.
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software that feeds back information to them on
performance measure scores? Research could offer
input to the design of EHR features in terms of how
clinicians and clients interact with the software, e.g.,
how do clinicians and clients engage with web-based
tools for screening and reporting results of
screening, treatment of substance use disorders,
communication between clinicians and clients, or
communication among clients or among
consulting clinicians?
 What is the validity of performance measurement
data collected through EHRs? Despite all the
possibilities that are and will become available
through EHRs, data validation still will be needed
because the new technology is not a panacea [45].
Issues will remain such as clients’ accurately
recalling or truthfully revealing their use of alcohol
or drugs or clinicians responding to stigma by failing
to record drug or alcohol abuse.
 How might EHRs be designed and implemented to
deal with 42CFR regulations? For example, decision
support software could be incorporated to prompt
clinicians to get explicit approval for sharing data.
Connection with broader measurement efforts
The treatment of individuals with substance use disor-
ders has never been limited to specialty substance abuse
treatment settings. The impetus for integration with
general medical care has accelerated, however, with the
national support for screening and brief intervention in
primary care settings [46], the development of health
homes (also known as medical homes) that are account-
able for individuals and their overall care, and a renewed
focus on community health centers as sites of services
[47]. Moreover, there is a renewed focus on care coord-
ination with the publication of a framework for meas-
urement and compendium of existing measures [48].
Researchers need to consider the following questions,
working collaboratively with the addiction field, those
focused on performance measures for medical condi-
tions, and those focused on performance measures for
care coordination:
 What are ways that the recognition of substance use
disorders influences performance measures in other
areas within the health care and in other sectors
(e.g., success in employment/school)? Specifically,
what is the impact of diagnosis of substance use
disorders on medical care quality, especially for
chronic medical conditions?
 How is the quality of treatment for substance use
disorders related to the quality of medical treatment
including preventive services or treatment for chronicconditions? For example, are organizations that
provide better quality of treatment for substance use
conditions also the ones providing better quality of
treatment for other conditions? Does better quality
of treatment for substance abuse conditions result in
better outcomes for other conditions, such as
diabetes or mental health conditions?
 What are key transitions and linkages for which
performance measures should be developed: between
levels of care in specialty treatment for substance
use disorders; between sectors of the substance use
and general medical treatment systems; and among
other systems that impact clients (e.g., educational,
criminal justice, and substance use prevention)?
 How can data be integrated and coordinated, as a
basis for performance measures across treatment
settings (e.g., medical or health homes, specialty
medical settings, specialty behavioral health settings,
and primary care) and across systems (e.g.,
treatment settings, criminal justice, and housing)?Implementation of performance measures for
accountability and quality improvement
The third main area of recommendations for research is
focused on what facilitates or impedes successful imple-
mentation of performance measures. For widespread
adoption, implementation also warrants attention
[2,49,50]. In this area, important lessons may come from
best practices for implementation borrowed from gen-
eral medicine, education, business/industry, manufactur-
ing, or agriculture. Examples of best practices related to
performance measures from other sectors may offer les-
sons on determining which incentives are most effective,
setting goals, dealing with poor performance or feeding
information back to treatment providers and clinicians.
In this section we first focus on descriptive studies that
are needed to understand the current environment in
which implementation of performance measures could
take place. Next, we outline additional work related to
implementation that pertains to capacity requirements,
reporting on the results of performance measures to
providers and the public, the role of incentives in im-
proving performance, and the impact of public policies
and cost considerations on the implementation of per-
formance measurement.Understanding the current implementation of
performance measures
Despite widespread use of performance measures, there
is not yet systematic understanding of where and how
they have been implemented. This area of fast-paced
change makes the design of these studies challenging in
order that they not be obsolete as soon as they are
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are needed to describe:
 What performance measurement is currently
underway, by which groups using which performance
measures (e.g., specialty treatment programs,
Medicaid, commercial health plans, or states)?
 What results of performance measurement are
available and how are they used. (e.g., public
reporting, quality improvement
efforts, incentive payment initiatives, or
accountability for payment)?
 What are various stakeholders’ roles in determining
which performance measures to adopt and
educating clinicians and treatment programs about
the measures (e.g., state agencies, providers,
consumers)?
 What level of effort is in place, particularly in state
agencies, to implement performance measures in
terms of staffing, data capacity, and evaluation of the
implementation (e.g., training and technical support
related to the use of measures)?
Understanding capacity requirements for using performance
measures
In order to implement performance measures, multiple
players need a basic capacity to collect data, calculate
measures and use these measures. Therefore, studies of
current capacity of states, treatment providers and
others also are required regarding:
 What minimal or optimal infrastructure is needed to
implement performance measurement? What is the
current capacity of specialty treatment programs for
performance measurement, and what capacity is
needed including minimum size (numbers of clients
served), technology, staffing and training in data
collection and interpretation, or resources?
 What are states’ and treatment programs’ current
capacities to interface with each other, especially as
this relates to using newer technologies such as EHRs
as a tool for performance measurement?
 How do the methods by which performance measures
are selected (e.g., imposed vs. chosen with
clinician and treatment program participation)
influence use of measures and improvement in
performance?
 How do different levels of performance monitoring,
reporting or accountability impact performance
(e.g., treatment program, clinician group, or specific
clinician levels)?
 What is the impact on implementation of
performance measures of organizational culture/
leadership, clinician education, incentives foradoption or sanctions for lack of adoption of
performance measures, or participation in national
programs such as NIATx?
Reporting results of performance measures
The impact of reporting to consumers, clinicians, hospi-
tals and health plans has been widely studied in the
medical sector. Reporting on the impact of performance
measures for substance use disorders is much less preva-
lent, although some states make provider-level informa-
tion available to the general public (e.g., North Carolina
and Oklahoma) and client-specific information to provi-
ders only (e.g., Oklahoma) [14]. Currently, there is little
research on these reports in terms of how often provi-
ders or the public access them and how they use them
for quality improvement, accountability or selecting sites
to seek treatment. Knowledge of consumers’ understand-
ing and use of performance measures may be an import-
ant component of developing new approaches to
patient-centered care.
Moreover, it is well accepted that clients with sub-
stance use disorders differ from those seeking medical
care in terms of readiness for treatment, co-occurrence
of mental health problems, and coercion into treatment.
How these differences influence consumers’ use of pub-
lic reports on the performance of treatment programs or
clinicians has not yet been studied. Thus, research
addressed at answering the following questions would be
fruitful both in terms of reporting to consumers and
reporting to treatment programs and clinicians.
 What information do consumers of services to treat
substance use disorders, or their families, want or
need when they look for treatment services?
 What would increase consumers or their families to
awareness and use of publically reported
information?
 What is the impact of providing feedback on
performance to treatment programs in terms of
changes in scores on process-focused performance
measures or clients’ outcomes?
 How do we package data for treatment programs or
clinicians to most likely be used for performance
improvement efforts?
 How can EHRs be used to offer client-specific
feedback regarding meeting performance measures
requirements to clinicians on a timely basis to
facilitate the use of the information for quality
improvement?
Incentives for performance improvement
Performance-based contracting, in which payment is
contingent upon meeting specified performance levels,
has been implemented for general medicine [51-53] and
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demonstrations at the federal level [54]. Effectiveness
evidence is mixed, however [55].
The lag in pay-for-performance focused on substance
use disorders has been due, in part, to less consensus
on performance measures and improvement strategies
[56] and less suitable state data to support it. None-
theless, some states have implemented this approach:
Delaware had adopted it for outpatient treatment pro-
grams but recently dropped it [57,58]; Maine imple-
mented performance-based contracting for substance
abuse in the early 1990’s and a restructured version in
2007 [59-61]; Connecticut had a pilot project on con-
nection to a lower level of care after intensive residen-
tial treatment and readmission to detoxification; and
Massachusetts is in the planning stages [62]. In spring
2011, SAMHSA announced new requirements in the
Block Grant applications for States to collect perform-
ance and outcome data which ultimately will be used
to determine if States receive an incentive based on
performance [63].
Incentive-based payment approaches will be promul-
gated more widely, and thus research should address a
broad range of questions listed below. Ideally, research-
ers could capitalize on new implementation of incentive-
based payment schemes to embed randomized design to
examine the impact on quality. The questions listed
below are focused on the implementation of incentive-
based payment systems as they relate to selecting per-
formance measures and eliciting participation. Design of
the incentives is beyond the scope of this paper.
 What performance measures for substance use
disorders currently are being used for incentive-based
payments?
 Are incentives based on performance measures
effective ways of promoting adoption of evidence-
based practices and new technologies by clinicians
who treat individuals with substance
use disorders?
 What is the role of public recognition through
reporting on performance measures in influencing
performance improvement for facilities and
clinicians?
 What are unintended consequences of incentivizing
specific aspects of performance (e.g., changes in
performance in areas that are not the focus of the
performance measure)?
 What is the impact on client access and outcomes
when linking funding to different types of
performance measures (i.e., structure, process, or
outcome)?
 What elements in designing the implementation of
incentive-based schemes that might promotesustainability? (e.g., involving end users in selecting
and specifying the performance measures).
 How might incentives be designed to focus on
performance measures based on proximal (during
treatment) outcomes rather than longer term
outcomes?Policy and cost impacts on implementation of performance
measures
Policies at the federal, state and local levels, in addition
to the cost of performance measurement, potentially can
influence their implementation. Research understanding
these influences is necessary for any successful imple-
mentation of measures. Potential research questions
include:
 How do federal, state and local policies drive the
types of performance measures for substance use
disorders that are implemented? As noted above,
SAMHSA’s changes to the Block Grant applications
for both substance abuse and mental health (which
optionally can be combined), will place a greater
emphasis on performance measures at the
state level.
 What is the impact of health reform legislation?
With the new emphasis under health reform on
health homes and on integration of primary and
specialty care, research is needed to evaluate
how performance measures are used in
these settings.
 Do structural barriers on treatment retention bias
possible improvement in performance measures
because individuals may not receive treatment for
services not covered by their insurance policies
(e.g., treatment for relapse management)?
 What are the cost implications of the inclusion of
performance measures for treatment programs
(e.g., data collection, staff time, interpreting and
acting on results)?
 Does the cost of implementing performance measures
at the state or treatment provider level outweigh the
potential improvements in quality of client treatment
and savings through more efficient provision of
services?Barriers and facilitators to measure development
and research
The complex health care environment presents chal-
lenges. Thus, the meeting participants also focused on
the need for understanding the barriers and facilitators
for research to support measure development and imple-
mentation. Investigation would be useful in studying the
following areas:
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performance measures for substance use disorders so
that the time period from measure conceptualization,
specification, testing and implementation can become
more rapid?
 What are specific audiences’ needs and the
implications for measure development and
implementation that is more audience targeted? For
example, might practitioners and consumers become
more involved in driving the development of
measures, e.g., by exploring some of the basic
tenants of participatory action research so that the
users of measures are involved at the inception of
measure development? Or, might treatment
program directors be included in development so
that the information they need to make crucial
decisions is included? Or, might clinicians weigh in
on the issue of considering clients’ outcomes
throughout the treatment process?
 What are the issues to consider in developing
performance measures for substance use disorders so
that the impact of unintended consequences can be
minimized? (e.g., measures that are not as easily
“gameable” through careful specification
and testing).
 What is the landscape on obstacles to information
exchange or data sharing that may preclude
performance measurement and/or protect clients,
particularly barriers to sharing information outside
of specific provider settings, between specialty
treatment and general medical treatment settings,
and across sectors such as integrating data from
educational systems? Both practical issues with data
sharing and legal issues such as 42 CFR structures
need to be better understood [64].
 With a new focus on EHR, might treatment programs
or clinicians be prompted to elicit clients’ permission
to share clinical information?Conclusion
Research focused on performance measures for sub-
stance use disorders is both exciting and challenging be-
cause it is conducted in a context that is changing in
some ways that we can anticipate and other ways that
we cannot easily envision. Performance measurement
for substance use disorders will need to adapt to new
approaches to treatment, federal regulations on parity
for behavioral health care, national health reform, and
an atmosphere of heightened interest in quality and per-
formance measures across the health care system. Given
the National Quality Strategy [65] and SAMHSA’s re-
sponse [66], performance measures need to place
substance abuse treatment in the context of person-centered care, which implies active roles for individual
clients and their families.
New measures will need to be developed and current
measures will need to be refined to take into account
new treatment approaches, such as the use of electronic
communication between providers and clients using new
technologies such as tablet computers and smart phones
that were not available even a few years ago. However,
dissemination of these innovations is not universal. For
example, electronic health records hold promise for
breakthroughs in performance measurement and quality
improvement, but they are not yet widely used or avail-
able within specialty substance use treatment.
Often tradeoffs will need to be considered between the
simplicity of a performance measure that may be easier
to implement more broadly versus a more complex
measure that may be better able to capture clinical qual-
ity but that may be more difficult to implement. There-
fore, research needs to be grounded in the current
environment and also forward looking in order to be
useful in a rapidly changing healthcare system.
Within this complex and changing environment, the
meeting reported on here offers a snapshot of current
topics and suggestions for research questions. We hope
that if these areas are studied, performance measures for
unhealthy substance use and substance use disorders will
better serve to support our common goals – improving
access and quality of care for individuals with substance
use disorders.
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